(ANIX) presented encouraging final results from its Phase 1 clinical trial of its investigational breast cancer vaccine at the 2025 San Antonio Breast ...
News
- Anixa Biosciences' Breast Cancer Vaccine Safe, Well Tolerated In Phase 1 Study
- Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer ...
Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium ... biotechnology company focused on the ...
- Wobble Genomics To Present New Data At SABCS Confirming Platform's Ability To ... - Yadkin Ripple
... San Antonio Breast Cancer Symposium (SABCS), taking place from December ... Wobble Genomics is an innovative healthcare and biotechnology ...
- Silicon Valley Tech Boss Snags $13.7M Upper East Side Townhouse - Hoodline
The company says its products are used by large banks, healthcare providers and biotech firms, according to Data Theorem. ... SAN ANTONIO SAN DIEGO ...
- Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the ... - The Manila Times
... San Antonio Breast Cancer Symposium ('SABCS”) today, Thursday, December 11 ... Celcuity is a clinical-stage biotechnology company pursuing development ...